Peter R. Dolan

DEFINITION of 'Peter R. Dolan'

A former CEO of Bristol-Myers. Dolan joined the company in 1988 and held various senior management positions, becoming president in 2000 and chairman in 2001, a position he held through 2005. Dolan was dismissed in September 2006 because of a patent dispute over the blood-thinning blockbuster drug Plavix, a major source of the company's revenues. The dispute led to major sales losses when a generic equivalent went on the market. Although he was fired, Dolan received a severance package worth $1.2 million and pension benefits worth about $9.5 million.

BREAKING DOWN 'Peter R. Dolan'

Born in 1956 in Massachusetts, Dolan earned his MBA from Dartmouth's Tuck School of Business in 1980. Privately-held Gemin X Pharmaceuticals appointed Dolan to its board in 2008. He has also served as chairman of the board of Pharmaceutical Research and Manufacturers of America (PhRMA).

RELATED TERMS
  1. Blockbuster Drug

    An extremely popular drug that generates annual sales of at least ...
  2. Patent Cliff

    A colloquialism to denote the potential sharp decline in revenues ...
  3. E. Linn Draper Jr.

    A former chairman, CEO and president of Ohio-based public utility ...
  4. Medical Patent

    A legal protection against market competition that a government ...
  5. Patent Reexamination

    A process conducted by the U.S. Patent and Trademark Office (USPTO) ...
  6. Jamie Dimon

    The chairman, CEO and former president of JPMorgan Chase & Co. ...
Related Articles
  1. Insights

    The Top 3 Exxon Mobil Shareholders (XOM)

    Learn about the three largest individual shareholders of Exxon Mobil Corporation (NYSE: XOM) stock, and the largest institutional and mutual fund holders.
  2. Insights

    Bristol-Myers' Earnings Forecasts a Healthy Dose of Growth

    You'd be hard-pressed to find a hotter health care stock with Bristol Myers' drug pipeline combined with its consistent execution.
  3. Investing

    Bristol-Myers Trades Ex-Dividend Wednesday (BMY)

    Bristol-Myers will send its dividend payment on August 22 to shareholders of record as of July 1.
  4. Markets

    Pharma Patent Trolls: Cheap Drugs At A Steep Price

    Though patent trolls can help patients achieve cheaper medication in the short-term, everyone pays for it in the long term.
  5. Markets

    How Bristol-Myers Squibb Makes the World Healthier

    Innovation and acquisition: an in depth look at pharma giant Bristol-Myers Squibb.
  6. ETFs & Mutual Funds

    PJP: PowerShares Dynamic Pharmaceuticals ETF

    Learn about the PowerShares Dynamic Pharmaceuticals exchange-traded fund, which specializes on investing in pharmaceutical companies.
  7. Investing

    The Risks And Rewards Of Pharma Stocks

    While pharmaceutical stocks have certain risks, big pharma companies have stable cash flows and pricing power, offering opportunities for profit.
  8. Markets

    What are the Federal Reserve Chairman's responsibilities?

    Learn about the duties and responsibilities of the chairman of the Federal Reserve Board, including testifying before Congress and as chair of the FOMC.
  9. Markets

    The Industry Handbook: Pharma Industry

    Learn about the pharmaceutical industry and discover the forces that influence this highly profitable and dynamic sector.
  10. ETFs & Mutual Funds

    Market Vectors Launches First Generic Drugs ETF (GNRX)

    Generic drugs have been a growing market in recent years. Now there is an ETF targeted at this market.
RELATED FAQS
  1. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  2. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  3. What are the differences between brand name drugs and generic drugs?

    Discover the process by which brand name drugs lose their patent, allowing generics to be manufactured, as well as the differences ... Read Answer >>
  4. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  5. Who are Pfizer's (PFE) main competitors?

    Learn about Pfizer's place in the pharmaceutical industry, and find out which major drug manufacturers are among its main ... Read Answer >>
  6. What countries comprise the majority of the global drugs sector?

    Find out which countries are the largest producers of pharmaceutical products in the world and why the United States dominates ... Read Answer >>
Hot Definitions
  1. Duration

    A measure of the sensitivity of the price (the value of principal) of a fixed-income investment to a change in interest rates. ...
  2. Dove

    An economic policy advisor who promotes monetary policies that involve the maintenance of low interest rates, believing that ...
  3. Cyclical Stock

    An equity security whose price is affected by ups and downs in the overall economy. Cyclical stocks typically relate to companies ...
  4. Front Running

    The unethical practice of a broker trading an equity based on information from the analyst department before his or her clients ...
  5. After-Hours Trading - AHT

    Trading after regular trading hours on the major exchanges. The increasing popularity of electronic communication networks ...
  6. Omnibus Account

    An account between two futures merchants (brokers). It involves the transaction of individual accounts which are combined ...
Trading Center